Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CCX 354-C · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| CCX354-C 100mg twice daily | EXPERIMENTAL | - |
| CCX354-C 200mg once daily | EXPERIMENTAL | - |
| CCX354-C | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CCX-354-C | DRUG | 200mg film-coated tablets once daily for 12 weeks + Methotrexate |
| Placebo | DRUG | Placebo film-coated tablets twice daily for 12 weeks + methotrexate |
| CCX354-C | DRUG | 100mg film-coated tablets twice daily for 12 weeks + methotrexate |
| CCX 354-C | DRUG | * Cohort 1: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days; * Cohort 2: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) twice daily for 14 days; and * Cohort 3: Eight subjects will be randomized to receive 200 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days. |
Inclusion Criteria: 1. Male or female subjects, aged 18-75 years inclusive, with functional class I to III rheumatoid arthritis (RA) based on American College of Rheumatology (ACR) criteria for at least 3 months prior to screening; wheel-chair bound subjects or those with irreversible disease will ...
Top 20 of 28 competitors
CCX 354-C is an investigational small molecule being developed for the treatment of rheumatoid arthritis. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with rheumatoid arthritis, including those partially responsive to methotrexate therapy.
CCX 354-C is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for rheumatoid arthritis.
CCX 354-C is in Phase 2 clinical development for rheumatoid arthritis. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. Two clinical trials have been completed, including a Phase 1 study and a Phase 2 study, with a total enrollment of 183 participants.
CCX 354-C has been studied in two completed clinical trials. NCT01027728 was a Phase 1 study evaluating safety and efficacy in 24 participants with rheumatoid arthritis in Belgium and Romania. NCT01242917 was a Phase 2 study in 159 participants with rheumatoid arthritis partially responsive to methotrexate, conducted across multiple European countries.
Yes, CCX 354-C is the same drug as CCX354-C. The name is written with and without a space in clinical trial records, but both refer to the same investigational small molecule being developed by Amgen Inc. for rheumatoid arthritis.